MiR-205 as predictive biomarker and adjuvant therapeutic tool in combination with trastuzumab-Reference-Cited by-同舟云学术

MiR-205 as predictive biomarker and adjuvant therapeutic tool in combination with trastuzumab

Published:2018-06-15 Issue:46 Volume:9 Page:27920-27928
ISSN:1949-2553
Container-title:Oncotarget
language:en
Short-container-title:Oncotarget

Author:

Cataldo Alessandra¹,Piovan Claudia¹,Plantamura Ilaria¹,D’Ippolito Elvira¹,Camelliti Simone¹,Casalini Patrizia²,Giussani Marta²,Déas Olivier³,Cairo Stefano³,Judde Jean-Gabriel³,Tagliabue Elda²,Iorio Marilena V.¹

Affiliation:

1. Start Up Unit, Experimental Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

2. Molecular Targeting Unit, Experimental Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

3. Xentech, Genopole Campus 3, Evry, Paris

Publisher

Impact Journals, LLC

Subject

Oncology

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Identification of genetic and immune signatures for the recurrence of HER2-positive breast cancer after trastuzumab-based treatment;Breast Cancer Research and Treatment;2023-04-21

2. The Role of MicroRNAs in HER2-Positive Breast Cancer: Where We Are and Future Prospective;Cancers;2022-10-29

3. Overview of MicroRNA Expression in Predicting Response to Neoadjuvant Therapies in Human Epidermal Growth Receptor-2 Enriched Breast Cancer – A Systematic Review;Breast Cancer: Basic and Clinical Research;2022-01

4. What if the future of HER2‐positive breast cancer patients was written in miRNAs? An exploratory analysis from NeoALTTO study;Cancer Medicine;2021-12-17

5. Circulating and Intracellular miRNAs as Prognostic and Predictive Factors in HER2-Positive Early Breast Cancer Treated with Neoadjuvant Chemotherapy: A Review of the Literature;Cancers;2021-09-29